Ubs Asset Management Americas Inc Vertex Pharmaceuticals Inc Transaction History

Ubs Asset Management Americas Inc

$345 Billion
Q2 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 2,584,327 shares of VRTX stock, worth $1.2 Billion. This represents 0.35% of its overall portfolio holdings.

Number of Shares

2,584,327

Previous 2,446,052 5.65%

Holding current value

$1.2 Billion

Previous $1.02 Billion 18.47%

% of portfolio

0.35%

Previous 0.37%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$392.81 - $485.53 $54.3 Million - $67.1 Million	138,275 Added 5.65%	2,584,327 $1.21 Billion
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $62.7 Million - $68.6 Million	-153,852 Reduced 5.92%	2,446,052 $1.02 Billion
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $59.6 Million - $71.4 Million	-173,895 Reduced 6.27%	2,599,904 $1.06 Billion
Q3 2023 Nov 13, 2023	SELL	$338.18 - $362.46 $12.8 Million - $13.7 Million	-37,932 Reduced 1.35%	2,773,799 $965 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $33.3 Million - $38 Million	-117,685 Reduced 4.02%	2,811,731 $886 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $65.5 Million - $73.7 Million	-229,276 Reduced 7.26%	2,929,416 $846 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $9.96 Million - $11.1 Million	36,378 Added 1.17%	3,158,692 $915 Million
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $4 Million - $4.98 Million	-17,023 Reduced 0.54%	3,122,314 $880 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $83 Million - $97.8 Million	-374,894 Reduced 10.67%	3,139,337 $819 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $134 Million - $169 Million	755,378 Added 27.38%	3,514,231 $772 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $55.7 Million - $62.4 Million	307,208 Added 12.53%	2,758,853 $500 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $71.6 Million - $84.5 Million	382,126 Added 18.46%	2,451,645 $494 Million
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $3.65 Million - $4.26 Million	-17,648 Reduced 0.85%	2,069,519 $445 Million
Q4 2020 Mar 01, 2021	BUY	$207.01 - $276.09 $97.9 Million - $131 Million	473,124 Added 29.31%	2,087,167 $493 Million
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $15.5 Million - $18.3 Million	60,494 Added 3.89%	1,614,043 $439 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $33.9 Million - $44.4 Million	150,223 Added 10.7%	1,553,549 $451 Million
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $9.29 Million - $11.5 Million	46,491 Added 3.43%	1,403,326 $334 Million
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $4.68 Million - $6.28 Million	-28,058 Reduced 2.03%	1,356,835 $297 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $1.45 Million - $1.63 Million	-8,710 Reduced 0.62%	1,384,893 $235 Million
Q2 2019 Aug 15, 2019	BUY	$164.61 - $190.37 $6.04 Million - $6.98 Million	36,663 Added 2.7%	1,393,603 $0
Q1 2019 May 14, 2019	SELL	$163.73 - $194.7 $415,710 - $494,343	-2,539 Reduced 0.19%	1,356,940 $0
Q4 2018 Feb 13, 2019	BUY	$151.91 - $192.21 $5.57 Million - $7.04 Million	36,635 Added 2.77%	1,359,479 $225 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $6.19 Million - $7.12 Million	-36,920 Reduced 2.72%	1,322,844 $0
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $18.8 Million - $21.9 Million	128,779 Added 10.46%	1,359,764 $0
Q1 2018 May 14, 2018	SELL	$151.6 - $177.13 $1.63 Million - $1.9 Million	-10,748 Reduced 0.87%	1,230,985 $0
Q4 2017 Feb 09, 2018	BUY	$137.28 - $155.55 $17 Million - $19.3 Million	123,996 Added 11.09%	1,241,733 $0
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $166 Million - $181 Million	1,117,737	1,117,737 $0

Others Institutions Holding VRTX

# of Institutions

1,707

Shares Held

226M

Call Options Held

1.2M

Put Options Held

1.59M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Vertex Pharmaceuticals Inc Transaction History